Despite a significant amount of preclinical data supporting MG1 as a potent oncolytic agent capable of generating antitumor immunity in murine cancer models, to date there is limited data on the ability of MG1 to support the generation of human antitumor T-cell responses, and what impact tumor size has on antitumor immune activation by MG1 or indeed other OVs. Here, MUC5B is linked to neoplasm.